Abstract
A 62-year-old woman with chronic lymphocytic lymphoma (CLL) who initially presented with lymphocytosis and 13q deletion in 1996 now presents to the clinic for recommendations regarding relapsed disease. The patient has received multiple prior therapies, including single-agent fludarabine, fludarabine and rituximab, and bendamustine and rituximab. She now has recurrent lymphocytosis with a WBC count that has increased from 13,000 2 months ago to 115,000 today and a platelet count of 55,000 but no lymphadenopathy. In addition, your evaluation finds that she has acquired a 17p deletion.
Cite
CITATION STYLE
Arnason, J. E., & Brown, J. R. (2011). Alemtuzumab use in relapsed and refractory chronic lymphocytic lymphoma. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 2011, 119–120. https://doi.org/10.1182/asheducation-2011.1.119
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
